~~<i id='510D50D4DE'><strike id='510D50D4DE'><tt id='510D50D4DE'><pre id='510D50D4DE'></pre></tt></strike></i>~~

Home» comprehensive» comprehensive

comprehensive

author：leisure time 2025-09-29 15:51:55 Page View：2915

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： N.Y. state detects polio case, first in the U.S. since 2013
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

focus

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

After Sarepta trial failure, Duchenne families brace for more debate

KristofferTripplaar/SipaviaAPTohearSareptaCEODougIngramtellit,theresultsMondayafternoonfromalargetri

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

1:30Twosixty-five-footraceyachtshadacloseencounterwithorcawhalesastheyapproachedtheStraitofGibraltar